The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis...
Transcript of The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis...
![Page 1: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/1.jpg)
The campaign on laboratory: focus on
Gallstone Disease and ERCP
Mauro Giuliani, MD, Specialist in Visceral Surgery, Vice Head Physician, Surgical Ward, Ospedale Regionale di Locarno
Alberto Fasoli, MD, Specialist in Gastroenterology, Chief Medical Service, Gastroenterology, Ospedale Regionale di Locarno e Bellinzona
Anna Zasa, MAS medical statistics and genomics, Quality and Patient Safety Service, Ospedale Regionale di Locarno
![Page 2: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/2.jpg)
2
Bilirubin tot. (surg) Y-GT (surg) Bilirubin (med) Y-GT (med)
![Page 3: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/3.jpg)
3
Gallstone disease
• Gallstone disease affects more than 20 million American adults at
a cost of 6.2 billion dollars per year.
• A subset of these patients will also have choledocholithiasis,
including 5-10% of those undergoing laparoscopic
cholecystectomy for symptomatic cholelithiasis and 18-33% of
patients with acute biliary pancreatitis.
• Missed common bile duct stones pose the patients at higher risk for
recurrent symptoms, pancreatitis and cholangitis.
• Morbidity and costs of indiscriminate diagnostic and/or invasive
biliary evaluation should be minimized.
ASGE-Guideline. The role of endoscopy in the evaluation of coledocholithiasis. Vol. 71, No.1: 2010 Gastrointestinal Endoscopy
![Page 4: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/4.jpg)
4
Laparoscopic Cholecystectomy
• Incidence of iatrogenic bile duct injuries is still higher in laparoscopic
cholecystectomy (0.2-0.5%) than in open cholecystectomy (0.1-0.2%)
• Injuries after laparoscopic cholecystectomies are more complex and associated
with higher morbidity and mortality than in open surgery
• Early diagnosis and management of iatrogenic bile duct injuries are linked to
better short- and long-term outcome
Iatrogenic Bile Duct Injuries, Identification, Classification and Management, Stewart L, MD. Surg C N Am 94 (2014) 297-310
![Page 5: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/5.jpg)
5
Surgical manipulation Diathermy Arterial injury Pneumoperitoeum
Evaluation and comparison of postoperative levels of serum bilirubin, serum transaminases and alkaline phosphatase in laparoscopic
cholecystectomy versus open cholecystectomy, Rikki Singal et al. J Gastrointestinal Oncol 2015;6(5):479-486
Laparoscopic Cholecystectomy Open Cholecystectomy
Effect of laparoscopy on liver tests
![Page 6: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/6.jpg)
6
> 68umol/l
> 50%
< 10%
ASGE-Guideline. The role of endoscopy in the evaluation of coledocholithiasis. Vol. 71, No.1: 2010 Gastrointestinal Endoscopy
A proposed strategy to assign risk of choledocholithiasis in
patients with symptomatic cholelithiasis on clinical predictors
=31-68umol/l
> 68umol/l
![Page 7: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/7.jpg)
7
Therapeutic Splitting
ASGE-Guideline. The role of endoscopy in the evaluation of coledocholithiasis. Vol. 71, No.1: 2010 Gastrointestinal Endoscopy
ERCP
Laparoscopic Cholecystectomy
MRCP
![Page 8: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/8.jpg)
8
Retrospective analysis of ERCP 2010-2016
198 ERCP procedures between 2010-2016 in
Locarno
73 excluded
26.3% (52 ERCP) Malignant disease
29 Pancreatic adenocarcinoma
13 Ampullar adenocarcinoma
4 Extrahepatic cholangiocarcinoma
4 Other
2 Multifocal hepatocarcinoma
10.5% (21 ERCP) Benign Disease
8 Obstructive IPMN (type-I,-II)
13 Other (autoimmune colangitis, chronic
pancreatitis)
125 ERCP procedures
77 (62%) Gallbladder in situ
48 (38%) After cholecystectomy
![Page 9: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/9.jpg)
9
0 (0%) 38 (30.4%) 87 (69.6%)
![Page 10: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/10.jpg)
10
Therapeutic splitting
Diagnostic procedures before ERCP High Ultrasound CT-Scan
MRCP
87 80 (92%) 36 (41%) 41 (47%)
Pos. 28 31 35
Neg. 52 5 6
Sensitivity 20.4% 96% 96%
Specificity 94.4% 88.8% 100%
77 (88.5%) ERCP: clearance of the CBD from gallestones was documented
10 (11.5%) ERCP: no visible passage of gallestones during the procedure
7 colangitis, 1 spontaneous gallstone passage, 2 sclerosis of the Papilla of Vater
![Page 11: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/11.jpg)
11
![Page 12: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/12.jpg)
12
![Page 13: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/13.jpg)
13
Best Cut-off for Bilirubin (gallbladder in situ) Clinical risk score cut-
off (ASGE)
61.8umol/l
Sensitivity = 59%, Specificity = 90%
68umol/l
27.1umol/l
Sensitivity = 60%, Specificity = 81.5%
31umol/l
![Page 14: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/14.jpg)
14
ASGE-Risk-
Score
High Intermediate p-value
Bilirubin
(umol/l)
85.00897 23.91818 3.934e-14
CBD-Diameter
(mm)
12.06667 9.45 0.007674
y-Glutamyl-
trasferase
372.73 258.81 0.10
Alkaline
Phosphatase
230.31 137.61 0.00029
AST 204.64 83.32 0.00241
ALT 256.45 120.017 0.00123
![Page 15: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/15.jpg)
15
Conclusions - The ASGE-Score is based on clinical predictors and ultrasound
and is a simple and less expensive score to evaluate the risk of
choledocholithiasis. Our data validate the ASGE-Risk-Score in our
population.
- In cases classified at high risk for choledocolithiasis, ERCP
followed by laparoscopic cholecystectomy (therapeutic splitting) or
“rendez-vous” intervention should be performed directly without
any other diagnostic imaging.
- The ASGE-Score should be part of our clinical decision making
tools in cases of suspected choledocholithiasis.
- Outcomes, quality and costs should be monitored in the run-in
phase.
![Page 16: The campaign on laboratory: focus on Gallstone Disease and ... filerecurrent symptoms, pancreatitis and cholangitis. • Morbidity and costs of indiscriminate diagnostic and/or invasive](https://reader031.fdocuments.in/reader031/viewer/2022011810/5e0162f792e2d4304b172f3a/html5/thumbnails/16.jpg)
16